ArticleDrugs - real world outcomes2026
Survival Outcomes with Guideline-Concordant Pediatric-Inspired Regimens in Adolescent/Young Adult Acute Lymphoblastic Leukemia: Retrospective Real-World Analysis.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric-inspired regimens (PIR) yield excellent outcomes for acute lymphoblastic leukemia (ALL). Despite national guidelines recommending PIR for adolescents and young adults (AYAs; aged 15-39 years), the use of guideline-concordant PIR in AYAs is inconsistent across treatment settings.
methodsThis retrospective observational study compared overall survival (OS) and stem cell transplant (SCT) use among AYAs treated with PIR versus non-PIR. Using a deidentified, geographically representative USA health claims database, we analyzed a cohort of AYAs with newly diagnosed ALL between 1 July 2007 and 30 September 2020.
resultsAmong 599 patients who met the inclusion criteria, 187 (31%) received PIR, 303 (51%) received non-PIR, and for 109 (18%), treatment was undetermined. PIR and non-PIR groups were propensity score matched (n = 187 each). Using Kaplan-Meier methodology, OS was significantly higher for those treated with PIR versus non-PIR (log-rank P = 0.0001; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.18-0.55). For PIR and non-PIR, 1-, 3-, and 5-year survival estimates (95% CI) were 98.1% (95.3-99.3%) versus 88.3% (83.5-91.7%); 88.5% (82.6-92.5%) versus 69.1% (62.1-75.1%); and 87.3% (81.0-91.6%) versus 63.3% (55.2-70.3%). Sensitivity and subgroup analyses were consistent with primary results. By Kaplan-Meier methodology, SCT use was significantly lower among AYAs treated with PIR than non-PIR (log-rank P = 0.0004; HR, 0.46; 95% CI 0.30-0.71); use by 2 years was 16.5% (12.2-22.2%) and 33.4% (27.6-40.0%), respectively.
conclusionsThese results support the use of guideline-concordant PIR for AYA ALL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.